Dr. Beckermann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 21st Ave S
Nashville, TN 37232Phone+1 615-936-2000Fax+1 615-936-0605
Summary
- Dr. Kathryn Beckermann is an oncologist based in Nashville, TN, specializing in the treatment of renal cell carcinoma. She completed her Internal Medicine residency and a fellowship in Hematology and Medical Oncology at Vanderbilt University Medical Center. Dr. Beckermann is actively involved in research, as demonstrated by multiple peer-reviewed publications including in esteemed journals like The Oncologist, Lancet, and Nature Reviews Clinical Oncology. Her research mainly revolves around advanced kidney cancer therapies.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2017- Vanderbilt University Medical CenterResidency, Internal Medicine, 2012 - 2014
Vanderbilt University School of MedicineClass of 2012
Certifications & Licensure
TN State Medical License 2014 - 2026
AL State Medical License 2020 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- syndrome-related congenital polycythemia and response to belzutifan.Paulo Siqueira Do Amaral, Sanjay R Mohan, Kathryn E Beckermann
Haematologica. 2024-12-01 - Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.Moshe C Ornstein, Laeth George, Wei Wei, C Marcela Diaz-Montero, Pat Rayman
Clinical Genitourinary Cancer. 2024-12-01 - Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.Othon Iliopoulos, Ane B Iversen, Vivek Narayan, Benjamin L Maughan, Kathryn E Beckermann
The Lancet. Oncology. 2024-10-01
Press Mentions
- Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell CarcinomaMarch 8th, 2021
Optimizing Benefit and Limiting Immune-Related Adverse Effects Following Checkpoint Inhibitor BlockadeJuly 3rd, 2018
May 16th, 2018 Young Lung Cancer Investigators Awarded $200K to Improve Lung Cancer OutcomesMay 16th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
